GlassScriptPhysician profile
Robert Joseph Chehade
NPI 1174713275
$1,187.48
in general payments reported to CMS, 2019-2025
14 companies · $6.10 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $90.24 · 2021: $54.94 · 2022: $169 · 2023: $407 · 2024: $68.47 · 2025: $6.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.02 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.48 | 2019-2020 | |
| Celgene Corporation | $136.94 | 2022-2023 | Zeposia |
| Pfizer INC. | $81.87 | 2019-2023 | |
| Ucb, INC. | $69.36 | 2019 | |
| Merck Sharp & Dohme LLC | $54.04 | 2019-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $46.78 | 2021-2023 | Gattex |
| Regeneron Healthcare Solutions, INC. | $41.81 | 2023 | Dupixent |
| Janssen Biotech, INC. | $30.38 | 2024 | Stelara |
| Organon LLC | $27.22 | 2023 | Hadlima, Renflexis |
| Phathom Pharmaceuticals, INC. | $26.75 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $18.79 | 2023 | |
| Covidien LP | $16.51 | 2019 | |
| Daiichi Sankyo INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chehade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.